Intellia
Intellia (NASDAQ: NTLA) is a publicly traded Gene & Genome Editing Platforms company founded in 2014 and based in Cambridge, United States.
Intellia Therapeutics was founded in 2014 and is based in Cambridge, Massachusetts. It develops in vivo CRISPR-based therapies, given as a single intravenous dose in lipid nanoparticles that edit a disease-causing gene in the liver. Lonvoguran ziclumeran (lonvo-z) for hereditary angioedema cut attacks by 87% versus placebo in the Phase 3 HAELO trial, and on Sept. 8, 2026 the FDA accepted its biologics license application with Priority Review and a March 10, 2027 action date. Nexiguran ziclumeran (nex-z), developed with Regeneron, is in two Phase 3 trials for transthyretin amyloidosis. Until a product is approved, Intellia's revenue comes from collaborations: $7.7 million in the second quarter of 2026. It trades on Nasdaq as NTLA. It raised about $195 million in net proceeds from an April 2026 stock offering, held $628.4 million in cash and marketable securities on June 30, 2026, and on Sept. 4, 2026 signed a senior secured credit facility of up to $400 million with OrbiMed, drawing $75 million at closing.
Lonvo-z puts a CRISPR therapy that edits genes inside the body before U.S. regulators: the FDA set a March 10, 2027 action date and did not plan an advisory committee. In Phase 3, 62% of patients given one infusion were free of attacks and of other therapy over six months, versus 11% on placebo. Intellia plans a U.S. launch in the first half of 2027, an outcome that bears on in vivo editing programs at CRISPR Therapeutics, Beam and Prime Medicine. Nex-z resumed Phase 3 enrollment in the second quarter of 2026 after an FDA clinical hold.
At a glance
Total raised
Undisclosed
Headcount
201-500
Headquarters
Cambridge
United StatesFounded
2014
Status
Public
Subsector
Biotech, ranked
Top 25 Biotech companies →Funding history
Total raised
—
Rounds tracked
0
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.
